Stock Research: 10x Genomics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

10x Genomics

NasdaqGS:TXG US88025U1097
91
  • Value
    79
  • Growth
    49
  • Safety
    Safety
    47
  • Combined
    76
  • Sentiment
    85
  • 360° View
    360° View
    91
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

10x Genomics, Inc. is a life science technology company providing integrated solutions for single cell and spatial biology. Its main businesses include instruments, consumables, and software for Chromium and Visium platforms, supporting single cell gene expression, immune profiling, ATAC, and spatial gene expression. The company operates globally. In the last fiscal year, the company had a market cap of $1,533 million, profits of $415 million, revenue of $611 million, and 1,306 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 91 (better than 91% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock 10x Genomics are very positive. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for 10x Genomics. The consolidated Sentiment Rank has a good rank of 85, which means that professional investors are more optimistic about the stock than for 85% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 79 or better than 79% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 47, meaning that the share price of 10x Genomics is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 49. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
47 55 12 9
Growth
49 19 59 59
Safety
Safety
79 75 60 54
Sentiment
85 9 79 71
360° View
360° View
91 18 61 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
35 20 39 38
Opinions Change
98 6 50 50
Pro Holdings
n/a 8 65 69
Market Pulse
72 60 89 70
Sentiment
85 9 79 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
47 55 12 9
Growth
49 19 59 59
Safety Safety
79 75 60 54
Combined
76 44 40 28
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
12 12 12 4
Price vs. Earnings (P/E)
57 61 11 9
Price vs. Book (P/B)
59 53 12 6
Dividend Yield
1 1 1 1
Value
47 55 12 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
10 60 79 82
Profit Growth
86 36 21 91
Capital Growth
68 44 4 7
Stock Returns
25 7 91 33
Growth
49 19 59 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
61 63 33 31
Liquidity
1 1 12 7
Safety Safety
79 75 60 54

Similar Stocks

Discover high‑ranked alternatives to 10x Genomics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.